Schedule 13D ownership disclosure

EPIRUS BIOPHARMACEUTICALS INC

Security class unavailable · CUSIP: 29428P107

Event date: 2015-02-06

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
1,671,400
Percent of class
12.9000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-15-007693
Form type
SC 13D/A
Filer
EPIRUS Biopharmaceuticals, Inc.
CIK
CIK 1135906
Filed
Feb 09, 2015
Reporting period
Feb 06, 2015
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub